Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial

CONCLUSIONS: In 12-15-month-old toddlers, a single dose of Pn-MAPS24v showed an acceptable safety profile, regardless of dose level; AEs were reported at similar frequencies by Pn-MAPS24v and PCV13 recipients. Pn-MAPS24v elicited IgG and OPA responses to all common and most unique serotypes. These results support further clinical evaluation in infants.PMID:38360475 | DOI:10.1016/j.vaccine.2024.02.001

Source: Vaccine - February 15, 2024 Category: Allergy & Immunology Authors: Dorota Borys Richard Rupp Ronald Smulders Gurunadh R Chichili Laura L Kovanda Vicki Santos Frank Malinoski George Siber Richard Malley Shite Sebastian Source Type: research